GlassScriptPhysician profile
Weiyi Gao
NPI 1760642961
$5,485.60
in general payments reported to CMS, 2019-2025
21 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2021: $673 · 2022: $737 · 2023: $1,046 · 2024: $1,242 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,289.54 | 2021-2025 | |
| Ucb, INC. | $900.90 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Eisai INC. | $510.15 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $271.80 | 2023-2025 | Rytary, Crexont, Ongentys |
| Allergan, INC. | $254.06 | 2019-2022 | |
| Lilly USA, LLC | $162.89 | 2023-2025 | Amyvid, Kisunla |
| Pfizer INC. | $157.53 | 2023-2025 | |
| Axsome Therapeutics, INC. | $149.93 | 2025 | Auvelity, Symbravo |
| Acadia Pharmaceuticals INC | $131.40 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $130.05 | 2025 | Ultomiris |
| Janssen Pharmaceuticals, INC | $124.99 | 2022 | |
| Janssen Biotech, INC. | $77.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $74.62 | 2021 | |
| Neurocrine Biosciences, INC. | $65.09 | 2024 | Ingrezza |
| Argenx US, INC. | $53.10 | 2025 | Vyvgart Hytrulo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $33.12 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.82 | 2025 | Austedo Xr |
| Nevro Corp. | $22.19 | 2024 | Senza |
| Myovant Sciences INC. | $20.29 | 2022 | |
| Impel Pharmaceuticals INC. | $18.05 | 2023 | Trudhesa |
| Biogen, INC. | $14.83 | 2024 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiyi Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.